Antibody-drug conjugates (ADC) are formed by the coupling of specific targeting monoclonal antibodies and highly active cytotoxic drugs through linkers. With their unique pharmaceutical properties, ADC drugs exhibit strong anti-tumor activity in the field of cancer therapy, while also offering higher safety compared to traditional chemotherapy. In recent years, the development of ADC drugs in … Read more
1 Introduction Antibody-drug conjugates (ADCs) are a new type of highly effective biopharmaceuticals that link antibodies with biologically active small molecule cytotoxic payloads through linkers. ADCs are designed to improve the therapeutic index (TI) of chemotherapeutic agents by selectively delivering cytotoxic drugs to tumor cells while reducing exposure in normal cells. Despite using a large … Read more
Source: YaoDu Written by: -7℃ Edited by: Wanzi ADC (Antibody Drug Conjugate) is a complex formed by linking cytotoxic drugs to monoclonal antibodies targeting tumors, which combines the characteristics of targeted drugs and chemotherapy drugs, enabling precise treatment. The concept of ADC drugs was proposed as early as 1900, but it remained theoretical for a … Read more
Antibody-drug conjugates (ADCs) have become a popular avenue for cancer treatment in recent years. They typically consist of monoclonal antibodies (mAbs) covalently linked to cytotoxic drugs (payloads) through chemically synthesized linkers. ADCs combine the advantages of high specificity targeting and effective killing action, achieving precise and efficient elimination of cancer cells. Figure 1. Structure and … Read more
Introduction: Antibody-drug conjugates (ADC) consist of antibodies, linkers, and small molecule cytotoxic drugs, combining high specificity and high cytotoxicity advantages. However, their structural diversity and complexity, along with the low content of released small molecule toxins in the circulatory system, pose significant challenges for pharmacokinetic studies. This article will discuss the mechanisms, design, safety features, … Read more
Antibody-drug conjugates (ADC) are a class of targeted cancer therapies that combine the high specificity of monoclonal antibodies with the potent activity of small molecule cytotoxic drugs to enhance tumor targeting and reduce side effects. Compared to traditional antibodies or antibody fragments, ADCs theoretically have higher efficacy due to their ability to release highly active … Read more
ADC In the era following chemotherapy, targeted therapy, and immunotherapy, ADC drugs, which combine cytotoxic drugs with targeted monoclonal antibodies, have opened a new era of fourth-line cancer treatment with exceptional results. They have become a significant class of new drugs in cancer treatment both domestically and internationally. So, what are ADC drugs (antibody-drug conjugates)? … Read more
Antibody-drug conjugates (ADC) are also known as “biological missiles”. They connect cytotoxic drugs similar to chemotherapy with monoclonal antibodies, consisting of three parts: antibodies, linkers, and payloads (small molecule cytotoxic drugs). This combination achieves the dual advantages of small molecules and antibody drugs, enabling targeted killing of tumors and other diseases. In recent years, global … Read more
Preface Preface Author Cloud Assistant Antibody-drug conjugates (ADCs) are a class of emerging drugs that combine the advantages of both antibodies and small molecule toxins. Compared to traditional cytotoxic drugs, ADCs have the advantages of strong targeting and fewer side effects, making them promising in the field of tumor therapy. To date, 11 ADC drugs … Read more
Introduction Antibody-drug conjugates (ADCs) typically consist of: highly specific and high-affinity antibodies, stable linkers, and potent small-molecule cytotoxic drugs1. The key to the development of ADCs lies in the selection of targets, antibodies, cytotoxic payloads, linkers, and the conjugation method. Among these, the conjugation method of ADCs directly determines the drug-to-antibody ratio (DAR), the distribution … Read more